Federal court finds two Latisse patents invalid

Article

The U.S. Court of Appeals for the Federal Circuit in Washington, D.C. recently found a pair of patents for Allergan’s Latisse (bimatoprost) invalid and threw out an order preventing Novartis’ Sandoz unit, Actavis, and generic drug company Apotex Inc. from selling their versions of the eyelash growth drug.

Washington, D.C.-The U.S. Court of Appeals for the Federal Circuit in Washington, D.C. recently found a pair of patents for Allergan’s Latisse (bimatoprost) invalid and threw out an order preventing Novartis’ Sandoz unit, Actavis, and generic drug company Apotex Inc. from selling their versions of the eyelash growth drug.

Latisse is a variation of the glaucoma drug Lumigan (bimatoprost). The patents, which are owned by Allergan and Duke University and were set to expire in 2022 and 2024, covered ways to apply the chemical compound to promote eyelash growth. Allergan recently estimated that Latisse sales would reach $100 million to $110 million in 2014. 

A patent on forms of Lumigan is set to expire in August, but Allergan won a lawsuit earlier this year involving a formulation for the 0.01 percent solution that will keep that specific version of the drug off the market through 2027. But Sandoz and other generic drug manufacturers are appealing that decision. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.